BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRIW
Biofrontera Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.81−0.02 (-1.94%)
Close on Oct 19, 2026
- Market cap
- $10.41M
- P/E (TTM)
- –
- Dividend yield
- –
Biofrontera Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q3 25 | Q2 25 | Q1 25 | Q3 24 | Q2 24 | Q1 24 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | – | – | – | – | – | – | – | – | $4.29M | $4.44M | $9.74M | $9.15M | – | – |
| Revenues Related Party [Member] | – | – | – | – | – | – | – | – | $32.00K | $16.00K | $15.00K | $15.00K | – | – |
| BFRhodo LED [Member] | – | – | – | – | – | – | – | – | – | – | $100.00K | – | – | – |
| Ameluz [Member] | – | – | – | – | – | – | – | – | – | – | $9.60M | – | – | – |
| Xepi [Member] | – | – | – | – | – | – | – | – | – | – | $100.00K | – | – | – |
| Ameluz LSA [Member] | – | – | – | – | – | $0 | $0 | $150.00M | – | – | – | – | – | – |
| Second A&R Ameluz LSA [Member] | – | – | $0 | $0 | $150.00M | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Biofrontera's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.